Alzheimer’s Drugs Market Share, Growth, & Report by 2030
[Research Report] The Alzheimer’s drugs market is projected to grow from US$ 6.21 billion in 2022 to US$ 22.01 billion by 2030; it is estimated to record a CAGR of 17.1% during 2022–2030.
Market Insights and Analyst View:
Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. The high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition are the key factors driving the Alzheimer’s drugs market growth. However, the side effects of drugs and the stringent regulatory environment hinder the market progress. Furthermore, the rising focus on personalized treatments and precision medicines for AD is expected to bring new Alzheimer’s drugs market trends in the coming years.
Growth Drivers and Restraints:
The growing cases of AD and related dementia propel the Alzheimer’s drugs market size. Alzheimer’s disease is the most common form of dementia worldwide, accounting for 60–70% of all cases. It is a progressive neurodegenerative disease that worsens gradually over the years and is more common in the aging population. As per the World Health Organization (WHO) report published in October 2022, the global population aged 60 years and above will grow to 1.4 billion by 2030 and reach 2.1 billion by 2050. This growing geriatric population is anticipated to increase the disease burden, facilitating the demand for related medical treatments in the coming years.
Furthermore, rising awareness about AD, improving diagnosis rates, and increasing investments in the development of new treatments are the growth enablers of the market. According to a report published by the Alzheimer’s Association in 2021, US$ 63 million was invested by the association in 2020 to advance Alzheimer’s and dementia research.
However, potential side effects express significant implications for the Alzheimer’s drug market progression. Acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists are the class of drugs commonly prescribed for the treatment of AD. Although these drugs are widely used and considered to be generally safe when used as directed, several specific side effects and concerns are associated with their use. The most significant adverse effects associated with AD drugs are dizziness, nausea, diarrhea, and abdominal pain in case of overdosing or when used inappropriately. This is a major concern and can impact consumer confidence in the product, potentially leading to decreased usage. According to an article published in 2021 by ScienceDirect Journal, studies carried out to evaluate adverse reactions of drugs used in the treatment of AD reported cardiac adverse events associated with AChEIs and gastrointestinal side effects such as constipation, diarrhea, vomiting, and abdominal pain associated with Memantine. Thus, the side effects of these drugs hinder the Alzheimer’s drugs market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Alzheimer's Drugs Market: Strategic Insights
Market Size Value in US$ 6.21 billion in 2022 Market Size Value by US$ 22.01 billion by 2030 Growth rate CAGR of 17.1% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Alzheimer's Drugs Market: Strategic Insights
![alzheimers-drugs-market](https://www.theinsightpartners.com/assets/rdimages/alzheimers-drugs-market-img1.png)
Market Size Value in | US$ 6.21 billion in 2022 |
Market Size Value by | US$ 22.01 billion by 2030 |
Growth rate | CAGR of 17.1% from 2022 to 2030 |
Forecast Period | 2022-2030 |
Base Year | 2022 |
![Analyst Image](https://www.theinsightpartners.com/assets/mrinal_kerhalkar.jpg)
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
![Analyst Image](https://www.theinsightpartners.com/assets/images/speak_analyst.gif)
Report Segmentation and Scope:
The “Alzheimer’s drugs market analysis” has been carried out by considering the following segments: drug classand distribution channel.
Segmental Analysis:
Based on drug class, the market is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment accounted for the largest Alzheimer’s drugs market share in 2022. The pipeline drugs segment is estimated to register the highest CAGR during 2022–2030. The cholinesterase inhibitors segment is further segmented into donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors are prescribed by specialists such as psychiatrists or neurologists for early- to mid-stage AD. These drugs boost the levels of acetylcholine in the brain, a neurotransmitter that helps nerve cells communicate with each other.
Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held the largest Alzheimer’s drugs market share. The online pharmacies segment is anticipated to register the highest CAGR during 2022–2030.
Regional Analysis:
The scope of the Alzheimer’s drugs market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the global market owing to the extensive research and development activities by pharmaceutical companies, and the prevalence of AD and associated dementia in the aging population in the region. According to the Alzheimer’s Association, in 2023, over 6 million people in America were diagnosed with AD, and ~1 in 9 individuals aged 65 years or above—representing 10.7% of the American population—were affected by Alzheimer’s disease. Additionally, according to statistics provided by the Centers for Disease Control and Prevention (CDC) in October 2020, AD is the sixth leading cause of death among US adults. Furthermore, the increasing spending on healthcare services across the US boosts the demand for AD treatment drugs, favoring the Alzheimer’s drugs market growth in the region.
Alzheimer's Drugs Market Report Scope
Industry Developments and Future Opportunities:
The Alzheimer’s drugs market forecast can help stakeholders in this marketplace plan their growth strategies. A few initiatives taken by key players operating in the global Alzheimer’s drugs market are listed below:
- In January 2024, Eisai Co., Ltd. and Biogen Inc. announced that the distribution of their collaborative development, LEQEMBI, has been approved in China. It is a humanized, anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody developed for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia.
- In May 2023, Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announced that their collaborative development, supplemental New Drug Application (sNDA) of REXULTI containing brexpiprazole, received the US Food and Drug Administration (FDA) approval for the treatment of neuropsychiatric symptom in Alzheimer’s and dementia.
- In May 2023, Eli Lilly and Company announced the positive result for TRAILBLAZER-ALZ 2 Phase 3 study of its Alzheimer’s drug, Donanemab. According to the study, Donanemab significantly slowed cognitive and functional decline in people with early symptomatic AD.
- In September 2022, Corium, Inc. launched ADLARITY, a donepezil transdermal system in the US. It is a prescription drug intended to treat mild, moderate, or severe dementia in patients with AD. This transdermal system is the first and only once-weekly patch that delivers consistent doses of donepezil through the skin and has no gastrointestinal side effects.
Competitive Landscape and Key Companies:
Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited are among the prominent players profiled in the Alzheimer’s drugs market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem.
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
Drug class, Distribution Channel, and Geography
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Key factors driving the Alzheimer’s drugs market growth include the high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition.
The Alzheimer’s drugs market was valued at US$ 6.21 billion in 2022.
The Alzheimer’s drugs market is expected to be valued at US$ 22.01 billion in 2030.
Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. Drugs from the class of cholinesterase inhibitors, NMDA receptor antagonists, and combination of these two are indicated for AD.
The Alzheimer’s drugs market, by drug class, is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment held a larger market share in 2022. The pipeline drugs segment is anticipated to register a higher CAGR during 2022-2030.
The Alzheimer’s drugs market majorly consists of the players such as Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Alzheimer's drugs Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Alzheimer's drugs - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Alzheimer's drugs - Global Market Analysis
6.1 Alzheimer's drugs - Global Market Overview
6.2 Alzheimer's drugs - Global Market and Forecast to 2030
7. Alzheimer's drugs – Revenue Analysis (USD Million) – By Product, 2020-2030
7.1 Overview
7.2 Cholinesterase inhibitors
7.2.1 Donepezil
7.2.2 Galantamine
7.2.3 Rivastigmine
7.3 NMDA Receptor Antagonist
7.4 Combination Drug
7.5 Pipeline Drugs
8. Alzheimer's drugs – Revenue Analysis (USD Million) – By End User, 2020-2030
8.1 Overview
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9. Alzheimer's drugs - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis
9.1 North America
9.1.1 North America Alzheimer's drugs Overview
9.1.2 North America Alzheimer's drugs Revenue and Forecasts to 2030
9.1.3 North America Alzheimer's drugs Revenue and Forecasts and Analysis - By Product
9.1.4 North America Alzheimer's drugs Revenue and Forecasts and Analysis - By End User
9.1.5 North America Alzheimer's drugs Revenue and Forecasts and Analysis - By Countries
9.1.5.1 United States Alzheimer's drugs
9.1.5.1.1 United States Alzheimer's drugs, by Product
9.1.5.1.2 United States Alzheimer's drugs, by End User
9.1.5.2 Canada Alzheimer's drugs
9.1.5.2.1 Canada Alzheimer's drugs, by Product
9.1.5.2.2 Canada Alzheimer's drugs, by End User
9.1.5.3 Mexico Alzheimer's drugs
9.1.5.3.1 Mexico Alzheimer's drugs, by Product
9.1.5.3.2 Mexico Alzheimer's drugs, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 Australia
9.3.2 China
9.3.3 India
9.3.4 Japan
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
9.4.1 South Africa
9.4.2 Saudi Arabia
9.4.3 U.A.E
9.4.4 Rest of Middle East and Africa
9.5 South and Central America
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Rest of South and Central America
10. Industry Landscape
10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments
11. Competitive Landscape
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration
12. Alzheimer's drugs - Key Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
Note - Similar information would be provided for below list of companies
12.2 Siemens Healthcare GmbH
12.3 Teva Pharmaceutical Industries Ltd
12.4 GlaxoSmithKline plc
12.5 Sanofi
12.6 Novartis AG
12.7 AstraZeneca
12.8 AbbVie Inc
12.9 Eisai Co
12.10 Takeda Pharmaceutical Company Limited
13. Appendix
13.1 Glossary
13.2 About The Insight Partners
13.3 Market Intelligence Cloud
The List of Companies - Alzheimer’s Drugs Market
- Pfizer Inc.
- Siemens Healthcare GmbH
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Sanofi
- Novartis AG
- AstraZeneca
- AbbVie Inc.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.